Cantor Fitzgerald Keeps Neutral Rating on Amgen Amid Mixed Analyst Views
Cantor Fitzgerald has maintained its Neutral rating on Amgen Inc. with a price target of $400. The stock is currently trading at $403, just above the target, and boasts a P/E ratio of 25.1 and a PEG ratio of 0.79. The firm highlighted Amgen’s strong commercial execution, noting its 9.1% revenue growth over the past year to $38.1 billion, along with a robust gross profit margin of 71.9%.
The firm also referenced positive data from trials for Sjogren’s disease and adjusted expectations for Lp(a) following the HORIZON results. Cantor Fitzgerald observed that Amgen has regained its status as a consensus long position among investors, despite a relatively quiet catalyst calendar through the end of 2026.
InvestingPro’s analysis rates Amgen’s financial health as GREAT, suggesting the stock is undervalued based on its Fair Value assessment. The platform offers deeper insights through Pro Research Reports for Amgen and over 1,400 other US equities.
In related news, Amgen reported successful results from its OASIZ 301 Phase 3 trial for dazodalibep, targeting moderate-to-severe systemic Sjögren’s disease. The trial met its primary endpoint, showing significant improvements in systemic disease activity. Following these results, Oppenheimer reiterated its Outperform rating with a $450 price target, while Jefferies raised its target to $410. However, UBS lowered its target to $430, maintaining a Buy rating but expressing some concerns about the trial.